Phreesia stock tumbles on lowered 2027 revenue outlook

Shares of digital healthcare services platform Phreesia PHR.N slump 26.64% to $8.37 premarket

Co lowered fiscal 2027 revenue outlook due to reduced pharma client spending commitments

Co lowers FY 2027 revenue outlook to $510 mln-$520 mln from $545 mln-$559 mln

J.P. Morgan downgraded the stock to “neutral” from “overweight” and cut PT, while D.A. Davidson also lowered its PT.

J.P. Morgan says co’s strategy to slow subscription pricing to bolster retention makes sense, but shifting focus toward the more uncertain Network Solutions business appears poorly timed

20 analysts rate the stock "buy" on average; median PT is $25 - data compiled by LSEG

As of last day's close, co shares have dropped 32.6% YTD, underperforming the S&P 500's .SPX 7.3% fall